2

3
Crawford DE. Understanding the epidemiology, natural history and key pathways
involved in prostate cancer. Urology. 2009;73:4–10.

4
5
6
7
Crawford DE. Understanding the epidemiology, natural history and key pathways
involved in prostate cancer. Urology. 2009;73:4–10.

8
9
The US PrevenMve Services Task Force 2017 DraO RecommendaMon Statement on
Screening for Prostate Cancer: An InvitaMon to Review and Comment.
JAMA [0098-7484] Bibbins Domingo, Kirsten Año:2017 vol.:317 iss:19 pág.:1949 -
1950

10
11
Fizazi, Eur J Cancer 2016; 66: 125-30

12
13
14
15
16
Sweeney CJ, Chen YH, Liu G, et al. Long term efficacy and QOL data of
chemohormonal therapy (C-HT) in low and high volume hormone naïve metastaMc
prostate cancer (PrCa): E3805 CHAARTED trial. Ann Oncol. 2016; (suppl. 6; abstr
720PD) 27.
Gravis G, Boher JM, Chen YH, et al. Burden of metastaMc hormone- sensiMve prostate
cancer to idenMfy men more likely to benefit from early docetaxel. J Clin Oncol.
2017;35. (suppl 6S; abstract 136).

17
James MD, et al. The Lancet 2015

18
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-
94-92671-13-4.
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico
AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito
JE, Kueoel MR, Lang JM, McKay R, McKenney J, Neoo G, Penson DF, Pow-Sang JM,
Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Sprao DE, Teply BA, Tward J,
Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer, Version
1.2021. J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi:
10.6004/jnccn.2021.0008. PMID: 33545689.
21
22
23
Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging
Is Associated with Overall Survival in Metasta@c Castra@on-
resistant Prostate Cancer. Radiology. 2016 Jul;280(1):151-60. doi:
10.1148/radiol.2015150799. Epub 2016 Jan 25.

24
25
26
27
28
29
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-
94-92671-13-4.
Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, D'Amico
AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito
JE, Kueoel MR, Lang JM, McKay R, McKenney J, Neoo G, Penson DF, Pow-Sang JM,
Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Sprao DE, Teply BA, Tward J,
Shead DA, Freedman-Cass DA. NCCN Guidelines Insights: Prostate Cancer, Version
1.2021. J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi:
10.6004/jnccn.2021.0008. PMID: 33545689.
32
33
34
35
Maroto P, Solsona E, Gallardo E, Mellado B, Morote J, Arranz JÁ, Gómez-Veiga F, Unda
M, Climent MÁ, Alcarazxpert opinion on first-line therapy in the treatment of
castration-resistant prostate cancer. Crit Rev Oncol Hematol. 2016 Apr;100:127-36.

Ost P, Decaestecker. Prognostic factors influencing prostate cancer-specific survival

in non-castrate patients with metastatic prostate cancer. Prostate. 2014
Feb;74(3):297-305. doi: 10.1002/pros.22750.

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
Francini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume
of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
The Prostate. 2018;78:889–895.

51
Francini E, Gray KP, Xie W, et al. Time of metastaMc disease presentaMon and volume
of disease are prognosMc for metastaMc hormone sensiMve prostate cancer (mHSPC).
The Prostate. 2018;78:889–895.

52
53
54
55
F. Gómez-Veiga, A. Alcaraz-Asensio, J.M. Burgos-Revilla et al., Avances en Uro-
Oncología «OncoUrology Forum Special EdiMon»: lo mejor del 2020, Actas Urológicas
Españolas, hops://doi.org/10.1016/j.acuro.2021.09.001

56
57
58
Gómez-Veiga F, et al. Avances en uro-oncología «OncoForum»: lo mejor del 2019.
Actas Urol Esp. 2020.

59
62
Un análisis pormenorizado de estos avances es realizado en el capítulo
correspondiente de este Máster: Evolución de los pacientes del Registro Nacional de
cáncer de próstata hacia la resistencia a la castración. Factores pronós9cos y
predictores. Nomogramas y nuevos marcadores.

63
EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-
94-92671-13-4.
65
66
67
68
69